Trial Profile

SCD-Haplo: A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 03 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Sirolimus
Indications Sickle cell anaemia; Transplant rejection
Focus Therapeutic Use
Acronyms SCD-Haplo

Most Recent Events

22 Aug 2019 Status changed from active, no longer recruiting to discontinued.
24 Oct 2016 Status changed from recruiting to active, no longer recruiting.
27 Jan 2014 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com